home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Webinar on Pharmacovigilance and Drug Safety

 
  March 04, 2016  
     
 


Compliance Trainings, Online
2016-03-31


Description :

One of the reasons for good clinical practice (GCP) is to protect the subjects in a research trial. In all research the subjects’ well-being should be paramount Safety checks, procedures, and reporting are fundamental to any research study involving human subjects. This includes the timely detection and management of, adverse events (AE), serious adverse events (SAE), adverse reactions (AR), and suspected unexpected serious adverse reactions (SUSAR). In addition, excellent record keeping, follow-up, and reporting are essential so that appropriate decisions can be taken relating to study participants as well those which help steer the course of the study, based on emerging safety information. It is also important to collect safety information even when a treatment is on the market. In fact many marketing authorisation procedures require PASS studies be performed (post authorisation safety studies) in order to collect additional safety information. PSURs (periodic safety update reports) are required for post marketed drugs and companies have an obligation to collect any safety information for the lifetime of the product.

This course provides a background to safety reporting. There is a refresher on the definitions and reporting requirements of AE, SAE, AR and SUSARs, within a clinical trial. We look at the sources of safety information and discuss the evidence that points to the causality of an event. The change in the regulatory environment is reviewed and the role of conditional approval and PASS and PAES studies is also discussed.

The requirement of a DSUR (development safety update report) and PSUR (periodic safety update report) is covered.

Areas Covered in the Session :

AE, SAE, AR and SUSAR

How to determine causality

Reporting timelines

Sources of information, preclinical clinical, clinical and post marketing

Changes in the regulatory environment i.e. conditional approvals

PASS and PAES

Regulatory reports DSURs PSURs

Who Will Benefit:

Clinical Research Professionals

Compliance Departments

Regulatory Departments

Drug Safety

Research and Development

CROs

AROs

 

Any personnel that may be involved in safety reporting when conducting clinical trials or following the marketing authorization of a product

 
 
Organized by: Compliance Trainings
Invited Speakers:

Sue Fitzpatrick joined the Pharmaceutical Industry in 1980. She has been responsible for the management and audit of CRAs and clinical trials in a wide range of therapeutic areas. As former Head of Education and Training at the Institute of Clinical Research she was responsible for the provision of training courses for the industry and postgraduate courses in collaboration with several UK Universities.

 
Deadline for Abstracts: 2016-03-31
 
Registration:

For more information about this event please visit

https://compliancetrainings.com/SiteEngine/ProductDetailView.aspx?id=FDB1851

 

To register this webinar

https://compliancetrainings.com/siteengine/Login.aspx 

E-mail: suzzane.d@compliancetrainings.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.